Glucagon regulates hepatic inducible nitric oxide synthesis in vivo

Shock

Volumn 22, Issue 2, 2004, Pages 157-162

  Harbrecht, Brian G ^a,b   Perpetua, Michelle ^a   Fulmer, Melissa ^a   Zhang, Baochun ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

Cytochrome P450; Endotoxin; Hepatic function; Liver; Sepsis; Shock

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLIC AMP; CYTOCHROME P450; ENDOTOXIN; GLUCAGON; GLUCOSE; INDUCIBLE NITRIC OXIDE SYNTHASE; LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRATE; NITRITE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMORRHAGIC SHOCK; INFLAMMATION; LIVER CELL; LIVER FUNCTION; LIVER INJURY; NONHUMAN; NORTHERN BLOTTING; PROTEIN EXPRESSION; RAT; SEPSIS; SEPTIC SHOCK; WESTERN BLOTTING;

ANIMALS; ASPARTATE AMINOTRANSFERASES; BLOTTING, NORTHERN; BLOTTING, WESTERN; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCAGON; GLUCOSE; INFLAMMATION; LIPOPOLYSACCHARIDES; LIVER; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); RATS; RATS, SPRAGUE-DAWLEY; RNA; RNA, MESSENGER; SODIUM CHLORIDE; TIME FACTORS;

EID: 13644270647     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000131579.22409.33     Document Type: Article

References (42)

1. Southan GJ, Szabo C: Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem Pharmacol 51:383-394, 1996.
2. Rockey DC, Chung JJ: Regulation of inducible nitric oxide synthase in hepatic sinusoidal endothelial cells. Am J Physiol 271:G260-G267, 1996.
3. Vos TA, Gouro ASH, Klok PA, Havinga R, Goor HV, Huitema S, Roelofsen H, Kkuijiers F, Jansen PLM, Moskage H: Differential effects of nitric oxide synthase inhibitors on endotoxin-induced liver damage in rats. Gastroenterology 113:1323-1333, 1997.
4. Szabo C, Southan GJ, Thiemermann C: Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci USA 91:12472-12476, 1994.
5. Wray GM, Milar CG, Hinds CJ, Thiemermann C: Selective inhibition of the activity of inducible nitric oxide synthase prevents the circulatory failure, but not the organ injury/dysfunction, caused by endotoxin. Shock 9:329-335, 1998.
6. Harbrecht BG, Wu B, Watkins SC, Marshall HP Jr, Peitzman AB, Billiar TR: Inhibition of nitric oxide synthase during hemorrhagic shock increases hepatic injury. Shock 4:332-337, 1995.
7. Hierholzer C, Harbrecht B, Menezes J, Kane J, MacMicking J, Nathan CF, Peitzman AB, Billiar TR, Tweardy DJ: Essential role of induced nitric oxide in the initiation of the inflammatory response following hemorrhagic shock. J Exp Med 187:917-928, 1998.
8. Menezes J, Hierholzer C, Watkins SC, Lyons V, Peitzman AB, Billiar TR, Harbrecht BG: A novel nitric oxide scavanger decreases liver injury and improves survival after hemorrhagic shock. Am J Physiol 277:G144-G151, 1999.
9. Curran RD, Billiar TR, Stuehr DJ, Ochoa JB, Harbrecht BG, Flint SG, Simmons RL: Multiple cytokines are required to induce hepatocyte nitric oxide production and inhibit total protein synthesis. Ann Surg 212:462-469, 1990.
10. Melillo G, Taylor LS, Brooks A, Musso T, Cox GW, Varesio L: Functional requirement of the hypoxia-responsive element in the activation of the inducible nitric oxide synthase promoter by the iron chelator desferrioxamine. J Biol Chem 272:12236-12243, 1997.
11. 4 inhibit cytokine-stimulated nitric oxide synthase type 2 expression in isolated rat hepatocytes. Prostaglandins 52:103-116, 1996.
12. Harbrecht BG, Wirant EM, Kim Y-M, Billiar TR: Glucagon inhibits hepatocyte nitric oxide synthesis. Arch Surg 131:1266-1272, 1996.
13. Harbrecht BG, Taylor BS, Xu Z, Ramalakshmi S, Ganster RW, Geller DA: cAMP inhibits inducible nitric oxide synthase expression and NF-κB binding activity in cultured rat hepatocytes. J Surg Res 99:258-264, 2001.
14. Smith FS, Ceppi ED, Titheradge MA: Inhibition of cytokine-induced inducible nitric oxide synthase expression by glucagon and cAMP in cultured hepatocytes. Biochem J 326:187-192, 1997.
15. Taylor BS, deVera ME, Ganster RW, Wang Q, Shapiro RA, Morris SM Jr, Billiar TR, Geller DA: Multiple NF-κB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J Biol Chem 273:15148-15156, 1998.
16. Christ B, Nath A: Impairment by interleukin 1b and tumour necrosis factor a of the glucagon-induced increase in phosphoenolpyruvate carboxykinase gene expression and gluconeogenesis in cultured rat hepatocytes. Biochem J 320:161-166, 1996.
17. Deutschman CS, DeMaio A, Buchman TG, Clemens MG: Sepsis-induced alterations in phosphoenolpyruvate carboxykinase expression: the role of insulin and glucagon. Circ Shock 40:295-302, 1993.
18. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P, Guillouzo A: Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44:707-715, 1993.
19. Sewer MB, Morgan ET: Down-regluation of the expression of three major rat cytochrome P450s by endotoxin in vivo occurs independently of nitric oxide production. J Pharmacol Exp Ther 287:352-358, 1998.
20. Roesler WJ, Vandenbark GR, Hansen RW: Cyclic AMP and the induction of eukaryotic gene expression. J Biol Chem 263:9063-9066, 1988.
21. DeVera ME, Shapiro RA, Nussler AK, Mudgett JS, Simmons RL, Morris SM Jr, Billiar TR, Geller DA: Transcriptional regulation of human inducible nitric oxide synthase (NOS 2) gene by cytokines: initial analysis of the human NOS 2 promoter. Proc Natl Acad Sci USA 93:1054-1059, 1996.
22. Kraus-Friedman N: Hormonal regulation of hepatic gluconeogenesis. Physiol Rev 64:170-259, 1984.
23. O'Riordain MG, Ross JA, Fearon KCH, Maingay J, Farouk M, Garden OJ, Carter DC: Insulin and counterregulatory hormones influence acute phase protein production in human hepatocytes. Am J Physiol 269:E323-E330, 1995.
24. Rosa JL, Ventura F, Tauler A, Bartrons R: Regulation of hepatic-6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase gene expression by glucagon. J Biol Chem 268:22540-22545, 1993.
25. Ito M, Uchijima Y, Arigo M, Seki T, Takenaka A, Hakuno F. Takakashi S, Ariga T, Noguchi T: Interaction between cAMP dependent and insulin-dependent signal pathways in tyrosine phosphorylation in primary cultures of rat hepatocytes. Biochem J 324:379-388, 1997.
26. 2+ influx induced by the action of dibutylhydroquinone and glucagon in the perfused rat liver. Biochem J 323:463-467, 1997.
27. Christophe J: Glucagon receptors: from genetic structure and expression to effector coupling and biological responses. Biochim Biophys Acta 1241:45-57, 1995.
28. Svoboda M, Tastenoy M, Vertongen P, Robberecht P: Relative quantitative analysis of glucagon receptor mRNA in rat tissues. Mol Cell Endocrin 105:131-137, 1994.
29. Kunz D, Muhl H, Walker G, Pfeilschifter J: Two distinct signaling pathways trigger the expression of the inducible nitric oxide synthase in rat renal mesangial cells. Proc Natl Acad Sci USA 91:5387-5391, 1994.
30. Imai T, Hirata Y, Kanno K, Masumo F: Induction of nitric oxide synthase by cyclic AMP in rat vascular smooth muscle cells. J Clin Invest 93:543-549, 1994.
31. Endres S, Fulle H-J, Sinha B, Stoll D, Dinarello CA, Gerzer R, Weber PC: Cyclic nucleotides differently regulate the syntheses of tumour necrosis factor-α and interleukin-1β by human mononuclear cells. Immunology 72:56-60, 1991.
32. Sung SJ, Walter JA: Increased cyclic AMP levels enhance IL-1α and IL-1β mRNA expression and protein production in human myelomonocytic cells lines and monocytes. J Clin Invest 88:1915-1923, 1991.
33. Hurme M: Modulation of interleukin-1β production by cyclic AMP in human monocytes. FEBS Lett 263:35-37, 1990.
34. Eigler N, Sacca L, Sherwin RS: Synergistic interactions of physiologic increments of glucagon, epinephrine, and cortisol in the dog: a model for stress-induced hyperglycemia. J Clin Invest 63:114-123, 1979.
35. Jordan ML, Rominski B, Jaquins-Gerstl A, Geller DA, Hoffman RA: Regulation of inducible nitric oxide production by intracellular calcium. Surgery 118:138-146, 1995.
36. 2+ selectively suppresses IL-1 induced NO production by reducing iNOS mRNA stability. J Cell Biol 129:1651-1657, 1995.
37. Gibbons GF, Khurona R, Odwell A, Seelaender MCL: Lipid balance in HEPG2 cells: active synthesis and impaired mobilization. J Lipid Res 35:1801-1808, 1994.
38. Lu SC, Kuhlenkamp J, Garcia-Ruiz C, Kaplowitz N: Hormone-mediated down-regulation of hepatic glutathione synthesis in the rat. J Clin Invest 88:260-269, 1991.
39. Fladmark KE, Gzertsen BT, Doskeland SO, Vintermyr OK: Fas/APO-1 (CD95)-induced apoptosis of primary hepatocytes is inhibited by cAMP. Biochem Biophys Res Commun 232:20-25, 1997.
40. Galea E, Feinstein DL: Regulation of the expression of the inflammatory nitric oxide synthase (NOS2) by cyclic AMP. FASEB J 13:2125-2137, 1999.
41. Zhang B, Liu S, Perpetua M, Walker WH, Harbrecht BG: c Jun suppresses cytokine-induced cyclic AMP response element (CRE) transcriptional activation in primary rat hepatocytes. Hepatology 39:1343-1352, 2004.
42. Park EA, Gurney AL, Nizielski SE, Hakimi P, Cao Z, Moorman A, Hanson RW: Relative roles of CCAAT/enhancer-binding protein β and cAMP regulatory element-binding protein in controlling transcription of the gene for phosphoenolpyruvate carboxykinase (GTP). J Biol Chem 268:613-619, 1993.